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Acute Administration of Fish Oil Inhibits Triggered Activity
in Isolated Myocytes From Rabbits and Patients
With Heart Failure
Hester M. Den Ruijter, PhD*; Géza Berecki, PhD*; Arie O. Verkerk, PhD; Diane Bakker, RA;
Antonius Baartscheer, PhD; Cees A. Schumacher, RA; Charly N.W. Belterman, RA;
Nicolaas de Jonge, MD, PhD; Jan W.T. Fiolet, PhD;
Ingeborg A. Brouwer, PhD; Ruben Coronel, MD, PhD
Background—Fish oil reduces sudden death in patients with prior myocardial infarction. Sudden death in heart failure may
be due to triggered activity based on disturbed calcium handling. We hypothesized that superfusion with 3-
polyunsaturated fatty acids (3-PUFAs) from fish inhibits triggered activity in heart failure.
Methods and Results—Ventricular myocytes were isolated from explanted hearts of rabbits with volume- and
pressure-overload–induced heart failure and of patients with end-stage heart failure. Membrane potentials (patch-clamp
technique) and intracellular calcium (indo-1 fluorescence) were recorded after 5 minutes of superfusion with Tyrode’s
solution (control), -9 monounsaturated fatty acid oleic acid (20 mol/L), or 3-PUFAs (docosahexaenoic acid or
eicosapentaenoic acid 20 mol/L). 3-PUFAs shortened the action potential at low stimulation frequencies and caused
an 25% decrease in diastolic and systolic calcium (all P0.05). Subsequently, noradrenalin and rapid pacing were
used to evoke triggered activity, delayed afterdepolarizations, and calcium aftertransients. 3-PUFAs abolished
triggered activity and reduced the number of delayed afterdepolarizations and calcium aftertransients compared with
control and oleic acid. 3-PUFAs reduced action potential shortening and intracellular calcium elevation in response to
noradrenalin. Results from human myocytes were in accordance with the findings obtained in rabbit myocytes.
Conclusion—Superfusion with 3-PUFAs from fish inhibits triggered arrhythmias in myocytes from rabbits and patients
with heart failure by lowering intracellular calcium and reducing the response to noradrenalin. (Circulation. 2008;117:
536-544.)
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Increased consumption of 3-polyunsaturated fatty acids(3-PUFAs) from fish reduces sudden death in patients
with prior myocardial infarction.1,2 Because sudden death
often is preceded by ventricular arrhythmias, these findings
suggest that fish oil is antiarrhythmic.
Clinical Perspective p 544
Arrhythmias in patients with heart failure (HF) often are
initiated by membrane potential oscillations related to distur-
bances in calcium handling, also referred to as triggered
activity.3,4 Isolated myocytes from rabbits with HF show
elevated levels of diastolic calcium, disturbed sarcoplasmic
reticulum (SR) calcium handling, and prolonged action po-
tentials leading to spontaneous SR calcium release (calcium
aftertransient).5,6 This sudden rise in calcium can, in turn,
cause membrane depolarizations because the excess calcium
is removed by the electrogenic sodium-calcium exchanger
(NCX).4,7 These membrane depolarizations, called delayed
afterdepolarizations (DADs), can initiate action potentials.4
The mechanisms underlying the antiarrhythmic action of
fish oil are poorly understood. Cellular experiments show that
acute administration of 3-PUFAs leads to action potential
shortening resulting from ionic remodeling of several ionic
currents such as sodium current (INa) and L-type calcium
current (ICa,L).8–10 A shorter action potential prevents calcium
overload and DADs11 as a result of the longer diastolic
interval and increased time for calcium removal.4 Further-
more, acute application of 3-PUFAs to normal myocytes
also decreases calcium transients, inhibits calcium sparks,
and reduces spontaneous calcium release from the SR.10,12,13
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We hypothesized that fish oil 3-PUFAs docosahexaenoic
acid (DHA) and eicosapentaenoic acid (EPA) inhibit DAD-
induced triggered activity in HF and normalize calcium
handling. We used an established arrhythmogenic rabbit
model of HF6,14 to study the effect of acute administration of
fish oil on the occurrence of triggered activity, DADs, and
calcium aftertransients. Superfusion with monounsaturated
9 fatty acid oleic acid (OA) was used as a control. In
addition, we confirmed the hypothesis in human myocytes
isolated from explanted hearts of patients undergoing cardiac
transplantation for end-stage HF.
Methods
Rabbit Model of Pressure- and
Volume-Overload–Induced HF
The investigation in rabbits was approved by the local ethics
committee and conformed to the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of
Health (NIH publication No. 85-23, revised 1996). HF was induced
in 20 rabbits (male; New Zealand White; specific pathogen free;
weight, 3 to 3.5 kg) by a 12-week period of combined volume and
pressure overload as described in detail previously.6,14 Briefly,
volume overload was induced by rupture of the aortic valve until
pulse pressure increased by 100%. Three weeks later, pressure
overload was created by a suprarenal stenosis of 50% of the
abdominal aorta. The rabbits received a normal diet that did not
contain fish oil or EPA and DHA.
The severity of HF was qualified on the basis of the following
parameters: left ventricular end-diastolic pressure 5 mm Hg, rela-
tive heart weight 5 g/kg, relative lung weight 3.5 g/kg, and the
presence of ascites.6 Rabbits were anesthetized by a combination of
ketamine (100 mg IM) and xylazine (20 mg IM) and heparinized
(5000 IU heparin, LEO Pharma, Buckinghamshire, UK). Then, left
ventricular end-diastolic pressure was measured with a fluid-filled
catheter (Portex fine-bore polythene tubing; internal diameter,
0.76 mm; outer diameter, 1.22 mm). Subsequently, the animal was
killed by an injection of pentobarbital (240 mg), and body weight,
heart weight, and lung weight were measured, as well as the presence
of ascites.6
Human Hearts
Human explanted hearts were obtained from 4 patients at the time of
cardiac transplantation. Table 1 lists the clinical characteristics of the
4 patients. The patients were in New York Heart Association class
IV and received standard therapy for chronic HF. Informed consent
was obtained before heart transplantation. The protocol complied
with institutional guidelines and the Declaration of Helsinki.
Myocyte Preparation and Test Perfusates
For cellular isolation of rabbit ventricular myocytes, both coronary
arteries were cannulated; for isolation of human myocytes, the
circumflex artery was cannulated.
A part of the ventricular wall was mounted on a Langendorff-
perfusion apparatus and subjected to Tyrode’s solution for 15
minutes, low-Ca2 Tyrode’s solution for 15 minutes, and low-Ca2
Tyrode’s solution containing a mixture of enzymes (collagenase type
B 0.15 mg/mL, collagenase type P 0.05 mg/mL, trypsin inhibitor 0.1
mg/mL, and hyaluronidase 0.15 mg/mL). After about 30 minutes of
recirculation with the Tyrode’s solution containing the enzyme
mixture at a flow rate of 30 to 50 mL/min, the left ventricular wall
was cut into small pieces and further fractionated using a shaking
protocol. For a more detailed description, see elsewhere.15,16
Before the experiments, myocytes were kept at room temperature
in separate vials, each containing105 myocytes in HEPES-buffered
solution (pH 7.3) containing (mmol/L) Na 156, K 4.7, Ca2 1.3,
Mg2 2.0, Cl 150.6, HCO3 4.3, HPO42 1.4, HEPES 17, and
glucose 11 supplied with 1% fatty acid free albumin. Small aliquots
of cell suspension were placed in a recording chamber on the stage
of an inverted microscope and allowed to adhere for 5 minutes.
Quiescent rod-shaped myocytes with cross-striations and smooth
surface were selected for measurements and superfused with Ty-
rode’s solution containing (mmol/L) NaCl 140, KCl 5.4, CaCl2 1.0,
glucose 5.5, and HEPES 5.0, pH 7.4 (NaOH). The microscope stage
and perfusion chamber were temperature controlled at 37°C.
The concentrations of EPA or DHA (20 mol/L) used in this study
were based on free fatty acid levels in the plasma of 6 patients
included in the Study on Omega-3 Fatty Acids and Ventricular
Arrhythmia (SOFA) trial17 who were taking 2 g/d fish oil. Plasma
free fatty acids were measured by gas-liquid chromatography.18
Results showed that the averaged concentration of free EPA and
DHA was 10 mol/L (range, 5.0 to 16.4 mol/L). The test
perfusates contained Tyrode’s solution (control calcium; 1.8 mmol/L
for action potential recordings and 2.6 mmol/L for calcium measure-
ments), OA (20 mol/L), 3-PUFAs DHA (20 mol/L), or EPA (20
mol/L). OA, an 9 monounsaturated fatty acid, was used as a
control fatty acid. We superfused the human ventricular myocytes
with fish oil fatty acid EPA or control fatty acid OA because of the
limited number of cells. Separate aliquots of myocytes were used for
electrophysiology and calcium measurements. The same cells were
used for the experiment before and after application of noradrenalin.
Action Potentials and DADs
Transmembrane potentials were recorded with the use of the
amphotericin-B perforated patch-clamp technique. Patch pipettes (1
to 3 mol/L) were pulled from borosilicate glass and filled with
pipette solution containing (mmol/L) K-gluconate 125, KCl 20,
NaCl 5, HEPES 10, and amphotericin-B 2.2, pH 7.2 (KOH). Data
acquisition and analysis were accomplished with custom software.
Membrane potentials were low-pass filtered with a cutoff frequency
of 5 kHz, digitized 10 kHz, and were corrected for liquid junction
Table 1. Patient Data
Patient 1 Patient 2 Patient 3 Patient 4
Age, y 60 66 48 54
Sex M M M M
Diagnosis ICM ICM DCM ICM
NYHA class IV IV IV IV
EF, % 14 22 21 14
Previous medications Bumetanide, digoxin,
acenocoumarol,
isosorbide mononitrate,
simvastatin, carvedilol,
spironolactone
Eplerenone, furosemide,
potassium chloride,
captopril,
acenocoumarol
Spironolactone, bisoprolol,
digoxin, amiodarone,
candesartan cilexetil,
bumetanide
Amiodarone, bumetanide,
spironolactone
ICM indicates ischemic cardiomyopathy; DCM, dilated cardiomyopathy; NYHA, New York Heart Association; and EF, ejection fraction.
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potentials. Action potentials were elicited at 0.5 to 4 Hz by 3-ms,
1.5 threshold current pulses through the patch pipette, except for
human action potentials, which were stimulated at 0.5 and 1 Hz.19
In each experiment, parameters from 6 consecutive action poten-
tials were averaged. After the 5-minute intervention with one of the
test perfusates, myocytes were challenged with noradrenalin for 1
minute (1 mol/L). Subsequently, spontaneous action potentials and
DADs were evoked by rapid pacing (10 seconds at 3 Hz) and
recorded during an 8-second pause. In human ventricular myocytes,
we used the highest possible pacing frequency to evoke triggered
action potentials and DADs. In a separate set of experiments, the
rapid pacing protocol was repeated 5 times in the same cell to ensure
reproducibility in the occurrence of triggered action potentials and
DADs in the same cell.
Calcium Transients and Aftertransients
Myocytes were loaded with indo-1. Dual-wavelength emission of
indo-1 was recorded (405/505 nm; excitation, 340 nm), and cellular-
free intracellular Ca2 concentration was calculated and calibrated as
described previously.20 Signals were corrected for background rec-
orded from indo-1–free myocytes (10% of raw signals).
Each experiment started with a conditioning 5-minute episode of
stimulation at 2 Hz (1.5 Hz for human ventricular myocytes) in the
presence of Tyrode’s solution. After the 5-minute intervention with
one of the test perfusates, myocytes were challenged with noradren-
alin (100 nmol/L) for 1 minute. Subsequently, calcium aftertransients
were evoked by rapid pacing (10 seconds at 3 Hz) and recorded
during an 8-second pause. For human ventricular myocytes, we used
the highest possible pacing frequency to evoke calcium aftertran-
sients. In a separate set of experiments, the rapid pacing protocol was
repeated 5 times in the same cell to ensure reproducibility in the
occurrence of calcium aftertransients in the same cell.
Drugs
OA, DHA, and EPA were prepared as 10-mmol/L stock solutions in
dimethyl sulfoxide and stored under nitrogen at 20°C. The fatty
acids were diluted in Tyrode’s solution to 20 mol/L and freshly
prepared before each single recording (used within 20 minutes).
Amphotericin-B was prepared as a 52-mmol/L stock solution in
dimethyl sulfoxide (kept at 4°C in dark for a maximum of 2 days)
and freshly diluted to 2.2 mmol/L daily.
Statistical Analysis
Data are meanSEM (n is number of cells; N is number of hearts).
Data were statistically analyzed with the t test, 1- or 2-way ANOVA
on ranks, or repeated-measures ANOVA if appropriate. Statistical
analysis was performed using the number of myocytes (n) assuming
independence between myocytes within hearts. The use of myocytes
as the unit for the statistical analysis was validated by calculating the
intraclass correlation coefficient. The variation between rabbits
(N	9) was less than the variation within rabbits as shown by the
negative intraclass correlation coefficient (0.104) for the action
potential duration at 90% repolarization (APD90). Multiple compar-
isons of groups after ANOVA were based on the Holm-Sidak or
Dunn test, depending on which was the most appropriate for the
group size and variance differences. If the main effects were
significant, means were compared by use of the Holm-Sidak method
(parametric ANOVA), or medians were compared through the use of
Dunn’s test (ANOVA on ranks). A value of P0.05 was considered
statistically significant. On the basis of the rabbit data on DADs, we
calculated that we required 10 myocytes per group (a minimum
detectable difference of means of 85% and an expected SD of 65%
with a desired power of 0.8 and an  of 0.05) to confirm our
hypothesis in human myocytes.
The authors had full access to and take responsibility for the
integrity of the data. All authors have read and agree to the
manuscript as written.
Results
Rabbit Data
The rabbit was included in the HF study group if 3 of the
following 4 criteria were met: (1) left ventricular end-diastol-
ic pressure 5 mm Hg, (2) relative heart weight 5 g/kg, (3)
relative lung weight 3.5 g/kg, or (4) the presence of ascites.
Of the 20 rabbits, 16 were included. In 6 animals, the severity
of HF precluded the measurement of left ventricular end-di-
astolic pressure (the anesthesia caused cardiac arrest). These
rabbits, however, met the 3 remaining criteria. Similar to
previous studies,5,6 the left ventricular end-diastolic pressure
of these failing animals was high at 21.84.3 mm Hg
(N	10); relative heart weight was 6.00.2 g/kg; relative
lung weight was 5.30.5 g/kg; and ascites was present in
87.5% of the HF rabbits.
3-PUFAs Inhibit Triggered Activity in Isolated
Myocytes From Rabbits With HF
Figure 1 shows representative examples of the effects of
3-PUFAs on transmembrane potentials (Figure 1A) and
intracellular calcium concentration (Figure 1B) in individual
rabbit myocytes in the presence of noradrenalin during and
after rapid pacing. The last stimulated action potential (Figure
1A) and last stimulated calcium transient (Figure 1B) of the
rapid pacing protocol in the presence of noradrenalin are
Figure 1. 3-PUFAs inhibit triggered
action potentials and reduce the number
of DADs and calcium aftertransients. A,
Representative examples of the last
stimulated action potentials (arrow) and
the tracing periods in control, OA, DHA,
and EPA. B, Representative examples of
the last stimulated calcium transient
(arrow) and the tracing period in control,
OA, DHA, and EPA. Stars point to spon-
taneous action potentials, DADs, and
calcium aftertransients. The action
potential and calcium measurements
were performed in different myocytes.
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indicated with arrows. Under control conditions (normal
Tyrode’s solution) and in the presence of OA, the last
stimulated action potential (Figure 1A) is followed by mul-
tiple triggered action potentials and a single DAD. In the
presence of DHA or EPA, triggered action potentials do not
occur (Figure 1A). Similarly, the last stimulated calcium
transient (Figure 1B) is followed by multiple calcium after-
transients under control conditions and in the presence of OA.
In the presence of DHA or EPA, calcium aftertransients do
not arise (Figure 1B).
Table 2 summarizes the averaged number of triggered
action potentials and DADs in control and in the presence of
OA, DHA or EPA. The number of triggered action potentials
and DADs is not significantly different between control and
OA or between DHA and EPA. Post hoc testing shows that
both EPA and DHA significantly reduce the number of
triggered action potentials and DADs compared with OA
and/or control (Table 2). The amount of calcium aftertran-
sients also is reduced in the presence of DHA and EPA (Table
2). The number of calcium aftertransients between control
and OA or between DHA and EPA is not different.
DHA or EPA Reduces the Sensitivity
to Noradrenalin
Because noradrenalin was used to evoke triggered activity,
DADs, and calcium aftertransients, we studied the effect of
noradrenalin on action potential duration and on diastolic and
systolic calcium concentrations in all groups. Figure 2A
shows typical examples of action potentials in the absence
() and presence () of noradrenalin in control, OA, DHA,
and EPA at a pacing frequency of 3 Hz. Superfusion with
noradrenalin for 1 minute shortens the APD90 in control, OA-,
or DHA-superfused but not in the EPA-superfused myocytes
(Figure 2B).
Figure 2C shows typical examples of calcium transient
recordings after 5 minutes of superfusion with control, OA,
DHA, or EPA in the absence () and presence () of
noradrenalin. The noradrenalin-induced increase in diastolic
and systolic calcium is less in the DHA- and EPA-superfused
myocytes compared with control and OA-superfused myo-
cytes. Figures 2D shows that that the average response of
diastolic calcium to noradrenalin is significantly lower in the
EPA-superfused myocytes compared with both control and
Table 2. Triggered Activity in Control and in OA-, DHA-, and EPA-Superfused Rabbit Myocytes
Rabbit Control OA DHA EPA
Triggered action potentials, n (n, N) 0.80.13 (6, 3) 0.90.20 (6, 3) 00*† (7, 3) 00*† (7, 3)
DADs, n (n, N) 1.80.11 (6, 3) 2.10.13 (6, 3) 1.00.15† (7, 3) 0.30.08*† (7, 3)
Calcium aftertransients, n (n, N) 2.70.65 (41, 15) 2.50.28 (43, 16) 1.50.37† (22, 9) 1.40.26*† (35, 11)
n indicates number of myocytes; N, number of hearts. Values are expressed as meanSEM.
*P0.05, significant difference vs control (ANOVA); †P0.05, significant differences vs OA (ANOVA).
Figure 2. 3-PUFAs reduce the sensitivity to noradrenalin. A, Representative examples of action potential recordings in control, OA,
DHA, and EPA in the absence and presence of noradrenalin. B, Changes in APD90 in response to noradrenalin (NA) in control (n	6;
N	3), OA (n	6; N	3), DHA (n	7; N	3), and EPA (n	7; N	3). *P0.05 indicates statistical differences with or without noradrenalin
(repeated-measures ANOVA). C, Representative examples of the intracellular calcium in control, OA, DHA, and EPA in the absence and
presence of noradrenalin. D and E, Diastolic (D) and systolic (E) calcium elevation in response to noradrenalin in control (n	40; N	15),
OA (n	35; N	16), DHA (n	20; N	9), and EPA (n	27; N	11). *P0.05 indicates statistical differences between DHA or EPA and con-
trol (ANOVA on ranks). #P0.05 indicates statistical differences between DHA or EPA and OA (ANOVA on ranks).
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OA-superfused myocytes. Figure 2E shows that the average
response of systolic calcium to noradrenalin is significantly
lower in both the DHA- and EPA-superfused myocytes
compared with control and OA-superfused myocytes. In
accordance, before the onset of rapid pacing, diastolic and
systolic calcium levels are significantly lower in the DHA-
(1029 and 34544 nmol/L; n	20; N	9) and EPA-
(1008 and 33327 nmol/L; n	27; N	11) superfused
myocytes compared with control (15211 and 51736
nmol/L; n	40; N	15) and OA-superfused myocytes (1499
and 57556 nmol/L; n	35; N	16).
Effects of -3 PUFAs on Action
Potential Duration
Figure 3A shows typical examples of action potential record-
ings before (t	0 minutes) and after 5 minutes (t	5 minutes)
of superfusion in control and with OA, DHA, and EPA at 1
Hz. On average, the APD90 of the myocytes in control and
after superfusion with OA was 2756 ms (n	21; N	6) and
2778 ms (n	7; N	3), respectively. Superfusion with DHA
or EPA resulted in a significantly shorter APD90, 2347 ms
(n	7; N	3) and 2418 ms (n	7; N	3), compared with
either control or OA. Figure 3B displays the frequency
dependence of APD90 in the 4 groups. In all groups, APD90
shortened with increasing stimulation frequencies. Note that
at stimulation frequencies of 2 Hz, no significant differ-
ences exist between groups. At all stimulation frequencies,
resting membrane potentials and action potential amplitude
were not different between groups (not shown).
Effects of -3 PUFAs on Cytoplasmic and
SR Calcium
Typical examples of calcium transients before (t	0 minutes)
and 5 minutes after (t	5 minutes) application of OA, DHA,
and EPA are shown in Figure 4A. Five minutes of superfu-
sion with DHA and EPA decreases diastolic and systolic
calcium levels more than control and OA. The decrease in
diastolic calcium and systolic calcium by DHA and EPA is
25%. At t	0 minutes, diastolic calcium and systolic cal-
cium are 1184.0 and 2685.5 nmol/L, respectively. After 5
minutes of superfusion, the diastolic and systolic calcium
levels are significantly more reduced by DHA and EPA than
in control conditions (Figure 4B and 4C). EPA causes a larger
reduction in diastolic and systolic calcium levels compared
with OA (Figure 4B and 4C).
At 5 minutes of superfusion, intracellular calcium levels
reached a steady state in all groups, and subsequent superfu-
sion with Tyrode’s solution did not change diastolic or
systolic calcium concentrations (not shown).
Human Data
3-PUFAs Inhibit Triggered Activity in Isolated Myocytes
From Patients With End-Stage HF
Figure 5A and 5B shows representative examples of trans-
membrane potentials and intracellular calcium concentrations
during and after rapid pacing (1 to 2 Hz for human myocytes)
in the presence of noradrenalin. Similar to our findings in
rabbit myocytes, the last stimulated action potential and the
last stimulated calcium transient (Figure 5A) are followed by
multiple triggered action potentials and a single DAD in the
OA-superfused human myocyte. None are present in the
EPA-superfused myocyte. Contrary to the rabbit myocytes,
human myocytes superfused with OA displayed early after-
depolarizations (EADs) (Figure 5A).
Table 3 summarizes the average number of triggered action
potentials, DADs, and calcium aftertransients and the inci-
dence of EADs in the presence of OA or EPA. The number of
DADs is significantly reduced in EPA-superfused myocytes
compared with OA. In addition, the incidence of EADs was
significantly reduced in the EPA-superfused myocyte com-
pared with OA. The difference in triggered action potentials
and calcium aftertransients between OA- and EPA-
superfused myocytes did not reach statistical significance.
Figure 5C and 5D shows typical examples of the effect of
noradrenalin on APD90 and intracellular calcium in OA- and
EPA-superfused human myocytes. In contrast to rabbit myo-
cytes, noradrenalin prolongs the APD90, as has been docu-
mented previously,19 and therefore was accompanied by
EADs in the OA-superfused human myocyte. The noradren-
alin-induced prolongation of the action potential is less in the
EPA-superfused myocyte and did not result in EAD forma-
tion. Similar to our rabbit data, noradrenalin causes an
increase in diastolic and systolic calcium. However, this
Figure 3. 3-PUFAs shorten the action potential at low stimula-
tion frequencies but not at higher pacing frequencies. A, Repre-
sentative examples of action potential recordings at 1 Hz before
(t	0 minutes) and after (t	5 minutes) superfusion in control
(n	21; N	3), OA (n	7; N	3), DHA (n	7; N	3), and EPA (n	7;
N	3). B, Dependence of APD90 on stimulation frequency.
*P0.05 indicates statistical differences between DHA or EPA
and control (ANOVA). #P0.05 indicates statistical differences
between DHA or EPA and OA (ANOVA).
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increase is similar in the EPA-superfused myocyte and the
OA-superfused myocyte (Figure 5D). The EAD formation
complicated accurate measurements of APD90 in the presence
of noradrenalin in OA-superfused myocytes. The absolute
increase in diastolic and systolic calcium in response to
noradrenalin was 55.7 and 7313.3 nmol/L in OA-
superfused myocytes (n	9: N	4) and 93.4 and 6713.1
nmol/L in EPA-superfused myocytes (n	8; N	4, P	NS).
Figure 5E and 5F shows typical examples of action
potentials and calcium transients after 5 minutes of superfu-
sion with either EPA or OA at a stimulation frequency of 1
Hz (action potential recordings) and 1.5 Hz (calcium transient
recordings) in the absence of noradrenalin. EPA causes a
pronounced shortening of the action potential and decreases
diastolic and systolic calcium levels compared with OA.
Before (t	0 minutes) the application of OA or EPA, APD90
was 52024.3 ms (n	23; N	3) at 1 Hz. After 5 minutes of
superfusion with EPA, the APD90 was shortened to 41222.6
ms (n	12; N	3; P0.05, ANOVA) in human myocytes.
After 5 minutes of superfusion with OA, the APD90 was
Figure 4. 3-PUFAs decrease diastolic
and systolic calcium concentrations. A,
Representative examples of calcium
transient recordings at 2 Hz before
(t	0 minutes) and after (t	5 minutes)
superfusion in control, OA, DHA, or
EPA. B and C, Reduction in diastolic
and systolic calcium levels after 5 min-
utes of superfusion with control (n	42;
N	15), OA (n	30; N	16), DHA (n	20;
N	9), or EPA (n	27; N	11). *P0.05
indicates statistical differences vs con-
trol (repeated-measures ANOVA).
#P0.05 indicates statistical differ-
ences vs OA (repeated-measures
ANOVA).
Figure 5. Representative examples in human myocytes. A, Representative example of the last stimulated action potential (arrow) and
the tracing period in OA- and EPA-superfused human myocytes. B, Representative examples of the last 7 stimulated calcium transients
(arrow) and the tracing period in OA- and EPA-superfused myocytes. C, Action potential recordings at 1 Hz in the absence (control)
and presence of OA or EPA. D, Calcium transient recording at 1.5 Hz in the absence (control) and presence of OA or EPA. E, Action
potential recordings after 5 minutes of superfusion with OA or EPA in the absence and presence of noradrenalin. F, Calcium transient
recordings after 5 minutes of superfusion with OA or EPA in the absence and presence of noradrenalin. The action potential and cal-
cium measurements were performed in different myocytes.
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51229.9 ms and did not differ from start values (t	0
minutes) (n	11; N	3 P	NS; ANOVA). Consistent with
previous findings,19 the human failing ventricular myocytes
could not be stimulated at high pacing frequencies (1 Hz)
during action potential recordings. Therefore, APD90 fre-
quency dependency was not obtained in the presence of OA
or EPA.
Before the onset of superfusion, diastolic and systolic
calcium levels were 835.8 and 14311.7 nmol/L (n	19;
N	4). EPA decreases diastolic and systolic calcium concen-
trations compared with OA (Table 3; P0.05, ANOVA).
In conclusion, the effects of 3-PUFAs on human ventric-
ular action potentials and calcium handling correspond
closely with those in isolated myocytes from rabbits with HF.
Discussion
Increased intake of fish oil is antiarrhythmic in patients with
prior myocardial infarction1,2 but not in patients with angina
or with sustained ventricular tachycardia.21,22 Patients with
prior myocardial infarction may suffer from arrhythmias
based on DADs resulting from disturbed calcium handling.
Therefore, the antiarrhythmic efficacy of fish oil may be
specific in HF. To investigate whether 3-PUFAs reduce
arrhythmias in HF, we used isolated myocytes from rabbits
with HF and isolated myocytes from patients with end-stage
HF. For the rabbit model, we applied combined pressure and
volume overload that induced HF over a period of 3 months.
In this model, a progressive increase in premature ventricular
beats and ventricular tachycardia is observed that appears to
have a focal origin.6,14,23 Isolated myocytes from these rabbits
with HF display high diastolic calcium levels, abnormal SR
handling, and action potential prolongation.5,24
Our results show that acute administration of 3-PUFA
DHA and EPA inhibits the formation of noradrenalin-induced
triggered activity and reduces the number of DADs and
calcium aftertransients compared with control and with
monounsaturated 9 fatty acid OA in isolated myocytes from
rabbits with HF. In addition, we confirm these findings in
isolated human myocytes from patients with end-stage HF.
The ionic mechanism underlying triggered action poten-
tials and DADs after a spontaneous calcium release is INCX.25
Inhibition of INCX by acute administration of fish oil, as
described previously,26–28 may be an additional mechanism
by which acute application of fish oil fatty acids contributed
to the reduction in triggered activity in our study. In addition,
a diet rich in fish oil enhances inward rectifier current and
shortens the action potential, thereby protecting against
DADs in calcium overload conditions.27
Fish Oil Reduces the Sensitivity for Noradrenalin
Our data show that acute administration of 3-PUFAs re-
duces the responsiveness to noradrenalin as observed by
reduced increases in diastolic and systolic calcium and
reduced changes in action potential durations in response to
noradrenalin. These reduced responses may be due to altered
properties of membrane currents and calcium regulating
proteins. However, acute application of 3-PUFAs also may
modulate the -adrenergic receptors or activation of the
G-protein/adenylyl cyclase/cAMP/protein kinase A pathway.
Although this may be an interesting additional mechanism by
which fish oil reduces sudden death in HF, further experi-
ments are needed to clarify this issue.
Cytoplasmic Calcium
Increased levels of diastolic calcium in HF are directly related
to the occurrence of calcium aftertransients.5 A decrease in
diastolic calcium concentrations by acute administration of
3-PUFAs may therefore explain the reduced occurrence of
calcium aftertransients in both our isolated rabbit and human
ventricular myocytes. Systolic calcium concentrations also
were markedly reduced by acute application of 3-PUFAs.
The finding that acute application of fish oil leads to
decreased levels of intracellular calcium has been described
previously in healthy rat myocytes.10,13 Reductions in intra-
cellular calcium by 3-PUFAs may be due to block of ICa,L10
and/or inhibition of the calcium release channels of the SR,
the ryanodine receptors in the SR membrane.12,13,29 Indeed,
acute administration of 3-PUFAs reduced the open proba-
bility of the ryanodine receptors in the SR membrane in
isolated SR vesicles.29,30 In our study, similar mechanisms
may account for the reduction in diastolic and systolic
calcium levels induced by 3-PUFAs.
In HF, a decrease in SR calcium content, combined with an
increase in diastolic calcium, is related to spontaneous cal-
cium releases from the SR.5 The role of the SR calcium
content by EPA and DHA in the reduction in triggered
activity seen in our study is unknown. However, acute
application of 3-PUFAs increased SR calcium content in
healthy rat myocytes.12,13 Further experiments are needed to
establish the effect of fish oils on SR calcium content in HF.
Fish Oil Shortens the Action Potential Durations
Action potential prolongation is characteristic of HF and
contributes to arrhythmogenesis.3 Action potential shortening
is an antiarrhythmic intervention for DAD-related arrhyth-
mias.4,11 In our study, the action potentials recorded from
both rabbit and human myocytes were shortened by acute
application of 3-PUFAs in both rabbit and human myocytes,
except at fast (2 Hz) stimulation rates (Figure 3B). The
shortening of the action potential by 3-PUFAs in human
myocytes may have contributed to a reduced number of
DADs. In rabbit myocytes, however, susceptibility to DAD
Table 3. Triggered Activity and Calcium Handling in OA- and
EPA-Superfused Human Myocytes
Human OA EPA
Triggered action potentials, n (n, N) 1.30.79 (11, 3) 0.20.16 (12, 3)
DADs, n (n, N) 1.00.28 (11, 3) 0.30.11* (12, 3)
EADs, % (n, N) 73 (11, 3) 17* (12, 3)
Calcium aftertransients, n (n, N) 2.21.32 (10, 4) 0.30.15 (11, 4)

Diastolic calcium, nmol/L (n, N) 92.7 (10, 4) 286.8* (9, 4)

Systolic calcium, nmol/L (n, N) 78.7 (10, 4) 469.7* (9, 4)
n indicates number of myocytes; N, number of hearts. Values are
meanSEM.
P0.05, significant differences vs OA (rank-sum test or ANOVA when
appropriate).
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formation was tested with a rapid pacing protocol (3 Hz) in
which action potential shortening was absent.
This excludes a role of action potential shortening by
3-PUFAs in the reduction of DADs in rabbit myocytes. Our
data correspond with previous studies showing that acute
application of 3-PUFAs shortens the action potential in rat,
rabbit, and guinea pig myocytes.8,31,32 However, at low
concentrations (10 mol/L) of 3-PUFAs, prolongation of
the rat action potential also has been reported.8
Circulating Versus Incorporated 3-PUFAs
What are physiological concentrations of free DHA and DHA
in humans? Data on free fatty acid concentration in the
plasma of patients from the SOFA trail17 supplemented with
2 g/d fish oil revealed that free EPA and DHA levels range
from 5 to17 mol/L. This corresponds to calculations done
by Negretti et al,13 who estimated that maximum levels of
free circulating 3-PUFAs are between 8 and 32 mol/L.
Our study shows that free EPA and DHA inhibit triggered
activity in concentrations that are clinically relevant.
A diet rich in fish oil leads not only to circulating free
3-PUFAs but also to incorporation of 3-PUFAs into
membrane phospholipids. In pig and rat myocytes, incorpo-
rated 3-PUFAs shorten the action potential but do not alter
calcium transients and diastolic calcium levels.26,27 The rela-
tive contribution of circulating versus incorporated 3-
PUFAs on intracellular calcium handling has yet to be
determined.
In this study, oleic acid was used as a control fatty acid.
The results indicate that oleic acid reduced diastolic and
systolic calcium concentration, although much less than the
3-PUFAs. Oleic acid did not inhibit triggered activity.
Therefore, monounsaturated fatty acids can be used as a
control fatty acid regarding cellular arrhythmogenesis.
Study Limitations and
Methodological Considerations
In this study, we used a rabbit model of HF that allows study
of the “trigger,” whereas patients with ischemic cardiomyop-
athy may suffer mainly from arrhythmias that are reentrant.
Although maintained by reentry, the arrhythmias in these
patients may be initiated by triggered activity.33 Another
difference between the rabbit and human myocytes is that the
human myocytes display prolongation of the action potential
in response to noradrenalin, whereas the rabbit myocytes
display a shortening of the action potential. Because EADs
are mainly bradycardia related and depend on a preexisting
long action potential,4 the noradrenalin-induced prolongation
of the action potential may explain the occurrence of EADs in
the human myocytes that are not present in the rabbit
myocytes. This study described 1 mechanism of arrhythmia;
definite answers regarding the efficacy of fish oil in HF in
humans who suffer from multiple types of arrhythmias will
come from the Gruppo Italiano per lo Studio della Streptochi-
nasi nell’Infarto Miocardico (GISSI) Heart Failure trial.34
Conclusion
Our data provide evidence for an antiarrhythmic action of
free circulating 3-PUFAs from fish in HF resulting from a
reduced sensitivity to noradrenalin and a reduction in diastol-
ic calcium.
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CLINICAL PERSPECTIVE
Fish oil supplementation reduces sudden death in patients with recent myocardial infarction. Arrhythmias in these patients
often are due to triggered arrhythmias that arise from early and/or delayed afterdepolarizations resulting from spontaneous
intracellular calcium releases. The mechanism by which fish oil reduces sudden death in patients with a preexisting cardiac
condition is unknown. In the present study, we tested whether fish oil fatty acids reduce arrhythmias that are evoked by
tachycardia and administration of noradrenalin in heart failure. Our study shows that physiological plasma concentrations
of fish oil fatty acids inhibit the formation of triggered arrhythmias in isolated myocytes of rabbits and in patients with heart
failure. The mechanism underlying the antiarrhythmic action of fish oil fatty acids is a decrease in intracellular calcium and
a reduced response to noradrenalin. Therefore, fish oil fatty acids prevent spontaneous intracellular calcium releases and
depolarizations. These findings suggest that the mechanism by which circulating fish oil fatty acids prevent sudden death
in patients with heart failure is, at least in part, due to inhibition of triggered arrhythmias. Whether fish oil supplements
can be safely administered in heart failure to prevent arrhythmias warrants more extensive testing in clinical trials.
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